Back to search

Article

Validation and Prospective Testing of a High Sensitivity, Quantitative Analytic Assay for HER2 on Histopathology Slides

2025-05-07

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Purpose</h4> The recent approval of antibody drug conjugates (ADCs) targeting HER2 (like Trastuzumab Deruxtecan or T-DXd) have led to challenges for the immunohistochemical (IHC) companion diagnostic test since the test was optimized for gene amplified levels of HER2. Here we develop and validate an objective test for low level HER2 expression toward more accurate selection of patients for T-...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
4b7c21dc-989c-5f1d-8434-58616a42b09c
DOI
10.1101/2025.05.06.25327097
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Validation and Prospective Testing of a High Sensitivity, Quantitative Analytic Assay for HER2 on Histopathology SlidesDOI 10.1101/2025.05.06.25327097
Prospective Assessment of a Quantitative Immunofluorescent Assay to Measure HER2 and TROP2 concentrations on a Single Tissue Biopsy SlideSemantic proximity
[Recent Advances in the Treatment of HER2-Altered Solid Tumors].Semantic proximity
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerSemantic proximity
Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic ConsiderationsSemantic proximity
Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplificationSemantic proximity
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast CancerSemantic proximity
From Categorical to Continuous: A Symbiotic Human-AI Approach to HER2 Scoring in the Antibody-Drug Conjugates EraSemantic proximity
Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples From Patients With Non-Small Cell Lung Cancer Treated With Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 Studies.Semantic proximity
Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes.Semantic proximity
Multiplexed RNA-FISH-guided Laser Capture Microdissection RNA Sequencing Improves Breast Cancer Molecular Subtyping, Prognostic Classification, and Predicts Response to Antibody Drug ConjugatesSemantic proximity
Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.Semantic proximity
Quantitative Protein Expression of Antibody–Drug Conjugate Targets in EGFR Mutated and Wild-type Non–Small Cell Lung CancerSemantic proximity
Select a neighboring publication to make it the new centre.